Product
Anti-EGFR-bispecific antibody armed activated T-cells
1 clinical trial
2 indications
Indication
Pancreatic CancerIndication
Pancreatic adenocarcinomaClinical trial
Phase Ib Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs)Status: Active (not recruiting), Estimated PCD: 2025-04-01